Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

he development of FDA-defined valvulopathy; the decline of Arena's research and development expenses; the planned reduction of Arena's workforce, including the expected size, timing, related charges and savings, and other expected impact of such reduction; Arena's ability to raise additional funds, including through its agreement with Azimuth; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs, the charges related to the recent reduction in Arena's workforce may be greater than anticipated, Arena may not realize the savings expected from this reduction, results of clinical trials or preclinical studies may not be predictive of future results, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing and ability of Arena to receive regulatory approval for its drug candidates, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be requ
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...FREMONT, Calif., Nov. 5 ...S), a leading developer of state-of-the-art geneti...er Sears, Ph.D. has joined the company,s Scientifi...designing and commercializing novel molecular diag...s, and on the development of computational biology...
(Date:11/5/2009)... LASIK Surgery and vision corre... directory were actively involved at the recently ...2009 Annual Meeting in San Francisco, California. ...MD, Dr. Jonathan Davidorf, MD, Dr. Peter Rapoza, M..., Dr. R. Wayne Bowman, MD, Dr. Edward Manche, MD, ...
(Date:11/4/2009)...HUNTSVILLE, Ala., Nov. 4 DIATHERIX...om ), today presented at the Michigan Security Ne...ce in Dearborn, Mich. Dennis Grimaud, Chairman and...he impact of the company,s advanced molecular diag...nse, infectious disease diagnosis and military eff...
(Date:11/4/2009)...SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ ...rted its financial results for the third quarter e...uarter ended September 30, 2009 improved to $31.0 ...oss of $37.0 million or $0.40 per share in the thi...ake improvements to its operating efficiencies as ...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
...ociates, Inc.,administrator for the HealthShares(T...the HealthShares(TM) Exchange-Traded Funds, today ... on Tuesday February 26, 2008, KV,Pharmaceutical C...ls, Inc.,(NYSE: BDY ) in the HealthShares(TM) Der...quired by Nycomed US Inc., a subsidiary of Nycomed...
...ration,(Nasdaq: BPUR ) today announced its financ...uary 31, 2008. For the quarter, the company report... share, compared with a net loss,of $6.9 million, ...eriod in,2007. Class A common shares outstanding o...,543,025, respectively., Revenues, Total revenue...
...ntered into an Agreement Under, Which Genmab Will ...ted in Brooklyn Park, Minnesot...ifornia, February 21, Genmab A/S (OMX: GEN) and PD... that they have entered into an agreement,under wh...ing facility,located in Brooklyn Park, Minnesota, ...
Other Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:11/4/2009).... Louis, MO, November 4, 2009 Childhood obesity i...ns. With more than one fourth of advertising on da...nd beverages and continuing questions about the ro...ember/December issue of the Journal of Nutrition ...ing aimed at children might be a large contributor...
(Date:11/4/2009)..., PORTOLA VALLEY, Calif., Oct. 19 ...olecular sensing and imaging devices which shed li...that it has signed exclusive distribution deals fo...nsors. The markets covered include Australia, New...enelux), Suriname, Italy, France, Spain, Portugal,...
(Date:11/4/2009)..., RIDGE, N.Y., Oct. 21 What,s the ...eventing accidental death resulting from prescript...s with good intentions, however, may be unaware th...ting their teens from the ticking timebomb of pres...leader in premium-quality medical supplies, has fo...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3AMA Medicare Campaign Kicks Off With New TV Ads 59585 1AMA Medicare Campaign Kicks Off With New TV Ads 59585 2AMA Medicare Campaign Kicks Off With New TV Ads 59585 3Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2
...of Standards and Technology (NIST) last week issue... and growing field of tissue engineering for medic...al tissue scaffold material that have been measure...es of porosity. , Three-dimensional tissue scaffo...adable materials that are meant to be implanted in...
...nt pieces of the climate change puzzle together is...is a key piece of this puzzle, but the size and sh...opardises the reliability of all current predictio...ct has been launched at the University of Leeds to...te. , Aerosols are small particles suspended in...
...f melanin -- the color pigment in skin and hair --...sed susceptibility to nicotine dependence and toba...rs, according to scientists., "We have found that...to the number of cigarettes smoked daily, levels o... African Americans," said Gary King, professor of ...
Other Biology News:NIST issues first reference material for tissue engineering 2Aerosol: A key piece of the climate change puzzle 2Skin color clue to nicotine dependence 2
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Annexin V Binding Buffer from BD Biosciences Pharmingen
Mouse Anti-Cytokeratin 8 + 18 + 19 Monoclonal Antibody, Unconjugated, Clone 2A4 from Abcam
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Biology Products: